Risankizumab outperforms secukinumab at one year
A phase 3b study investigating the efficacy and safety of risankizumab compared to secukinumab showed…
Pubblicazioni
Pubblicazioni
Clascoterone cream 1% targets androgen receptors
The topical cream is the first acne drug with a new mechanism of action to…
Pubblicazioni
An update on immunotherapy for melanoma
Until recently, the prospects for melanoma patients were bleak, but scientific breakthroughs have brought effective…